This page lists the cardiology hospitals in our directory offering Aortic Valve Repair in Dubai, UAE, including Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai. Each listing links through to the hospital's full profile page.
Ask us about aortic valve repair in Dubai, UAE
Share a few details and our care coordination team will get back to you with next steps.
Compare 3 accredited hospitals for Cardiology in Dubai, UAE
Featured🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Ranks #1 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Kings College Hospital Dubai
Ranks #2 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Aster Hospital Dubai
Ranks #3 in this list by listed rating (4.5/5 from 1 reviews).
How we selected these hospitals
A hospital appears on this page when Cardiology is among its listed specialties and it is located in Dubai, UAE. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Aortic Valve Repair in Dubai, UAE?
Choosing the right hospital for aortic valve repair is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include cardiology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Aortic Valve Repair
Aortic valve repair is a highly specialized cardiac surgical procedure that restores the native valve's structural integrity, eliminates regurgitation or stenosis, and preserves the patient's own tissue — avoiding lifelong anticoagulation therapy in most cases. Contemporary series from high-volume cardiac centers report procedural success rates exceeding 95% for repair-eligible anatomy, with 10-year freedom from reoperation above 85% in expert hands. GAF Healthcare connects international patients with JCI- and NABH-accredited cardiac centers in India and JCI- and DHA-accredited facilities in the UAE, offering world-class surgical expertise at a fraction of Western costs, with end-to-end care coordination from first consultation through safe repatriation. Hospital Stay: 7–12 days (ICU: 1–3 days; step-down ward: 5–9 days) • Total Stay in Country (Fit-to-Fly): 4–6 weeks (short-haul commercial flight); 6–8 weeks (long-haul flight exceeding 6 hours) • Success Rate: 95–98% procedural success; >85% freedom from reoperation at 10 years
Clinical Overview
The aortic valve sits at the outflow tract of the left ventricle, guarding the boundary between the ventricle and the ascending aorta. It normally consists of three semilunar cusps that open with each systolic ejection and coapt tightly during diastole to prevent backflow. Pathology disrupts this elegant mechanics in two principal ways: aortic stenosis (progressive calcific or congenital narrowing that obstructs outflow, generating left ventricular pressure overload, concentric hypertrophy, and eventually heart failure) and aortic regurgitation (cusp prolapse, perforation, fenestration, or annular dilatation that allows diastolic reflux, producing eccentric hypertrophy and progressive systolic dysfunction). Bicuspid aortic valve disease — the most common congenital cardiac malformation, present in approximately 1–2% of the global population — underlies a disproportionate share of cases in younger surgical candidates. Untreated severe aortic valve disease carries a dismal natural history. Symptomatic severe aortic stenosis is associated with an annual mortality of roughly 25% without intervention; severe aortic regurgitation with reduced ejection fraction similarly portends rapid clinical deterioration. The physiological burden extends beyond the heart: chronic pressure or volume overload drives maladaptive ventricular remodeling, pulmonary hypertension, atrial arrhythmias, and end-organ hypoperfusion. Early, precise intervention — ideally before irreversible myocardial injury occurs — is therefore the cornerstone of contemporary management. The standard of care for eligible patients is surgical aortic valve repair (SAVR) rather than replacement when feasible, because it eliminates prosthetic valve-related risks (thromboembolism, structural valve deterioration, and endocarditis), preserves normal hemodynamics, and, critically, avoids mandatory lifelong anticoagulation. Repair is guided by systematic echocardiographic and intraoperative assessment of cusp morphology, coaptation geometry, and annular dimensions. Where repair is not anatomically feasible, surgical valve replacement (with biological or mechanical prostheses) or catheter-based transcatheter aortic valve replacement (TAVR) remains highly effective. Leading centers in India and the UAE now perform the full spectrum of these interventions using robotic assistance, minimally invasive right anterior thoracotomy, and advanced intraoperative imaging — outcomes comparable to the best programs in North America and Europe.
Who is a Candidate?
• ELIGIBILITY — SURGICAL AORTIC VALVE REPAIR (SAVR): • Severe aortic regurgitation with cusp prolapse, leaflet perforation, or annular dilatation amenable to cusp resuspension, pericardial patch augmentation, or ring annuloplasty • Bicuspid valve with cusp fusion (commissurotomy) or prolapse (free-margin plication, triangular resection) • Aortic root dilatation with competent cusps: valve-sparing root replacement (David or Yacoub reimplantation technique) • Symptomatic severe aortic stenosis in younger or low-surgical-risk patients where valve preservation is anatomically feasible (e.g., Ozaki leaflet reconstruction using autologous pericardium) • Asymptomatic severe aortic regurgitation with progressive LV dilatation (LVESD >50 mm or indexed LVESD >25 mm/m²) or EF declining below 55% • ELIGIBILITY — TRANSCATHETER / HYBRID OPTIONS: • High or prohibitive surgical risk patients (STS-PROM ≥8% or EuroSCORE II ≥6%) with severe aortic stenosis: TAVR with balloon-expandable (SAPIEN 3) or self-expanding (Evolut PRO+) valve systems • Valve-in-valve TAVR for degenerated biological prostheses • REQUIRED DIAGNOSTIC WORKUP: • Transthoracic echocardiography (TTE): valve morphology, cusp number, mean gradient, valve area (AVA by continuity equation), regurgitant volume and fraction, LV dimensions and EF • Transesophageal echocardiography (TEE): 3D cusp anatomy, coaptation depth, annular dimensions — essential for surgical repair planning • Cardiac CT angiography (CCTA, ECG-gated, ≥256-slice): annular sizing for TAVR; aortic root and ascending aorta geometry; coronary artery evaluation • Coronary angiography or CT-FFR: to identify concomitant CAD requiring bypass • Cardiac MRI: precise quantification of regurgitant fraction and LV volumes when echocardiographic windows are suboptimal • Pulmonary function tests and renal function panel: perioperative risk stratification • Blood tests: CBC, CMP, coagulation profile, HbA1c, infectious serology (HIV, HBsAg, HCV) • CONTRAINDICATIONS / HIGH-RISK FLAGS: • Heavily calcified, immobile cusps with dense annular calcification (not amenable to repair; proceed to replacement) • Active infective endocarditis with annular abscess (relative — staged repair considered after antibiotic consolidation) • Severe uncorrectable coagulopathy • Porcelain aorta (renders conventional cardiopulmonary bypass high-risk; TAVR preferred) • Life expectancy <1 year from non-cardiac comorbidities • Frailty index scoring (Clinical Frailty Scale ≥6) without robust support system for rehabilitation
Treatment Options & Approaches
SURGICAL AORTIC VALVE REPAIR — TECHNIQUES: 1. Cusp Repair Techniques (for Aortic Regurgitation): • Free-margin resuspension: prolapsed cusp is re-anchored centrally with PTFE (Gore-Tex) sutures, restoring coaptation height • Triangular resection: removal of a triangular prolapsing segment with direct re-approximation • Pericardial patch augmentation: autologous or glutaraldehyde-fixed pericardium used to extend a retracted or perforated cusp to achieve adequate coaptation surface • Decalcification and shaving: careful endarterectomy of cusp calcifications to restore cusp mobility (feasible in selected cases) • Commissurotomy: incision of fused commissures in bicuspid valve stenosis 2. Annular Stabilization: • Subcommissural annuloplasty (Cabrol sutures): purse-string reduction of the interleaflet triangles to reduce annular dilatation • External annuloplasty rings (Hagl, Lansac): reinforce and downsize the ventriculo-aortic junction to restore geometric coaptation — now considered standard in repair programs aiming for durable results 3. Valve-Sparing Aortic Root Replacement (VSARR): • David Operation (reimplantation): the aortic root is excised, and the native valve is reimplanted inside a Dacron tube graft; achieves permanent annular stabilization • Yacoub Operation (remodeling): preserves more physiological root geometry; typically combined with an annuloplasty ring for long-term stability • Ideal for young patients with Marfan syndrome, bicuspid valve-associated root aneurysm, or idiopathic root dilatation with repairable cusps 4. Ozaki Aortic Valve Neocuspidization (AVNeo): • All three native cusps are excised and replaced with precisely templated, glutaraldehyde-fixed autologous pericardial leaflets • Avoids prosthetic implant, maintains near-normal hemodynamics; especially valuable in heavily calcified valves where conventional repair is unfeasible • Medium-term data (5–8 years) show low mean gradients and good freedom from reintervention SURGICAL AORTIC VALVE REPLACEMENT (SAVR): • Mechanical prostheses (On-X, St. Jude Regent): chosen for patients under 60 years willing to accept anticoagulation with warfarin (or novel low-INR protocols with On-X) • Biological prostheses (Carpentier-Edwards Perimount, Magna Ease; Medtronic Hancock; Inspiris Resilia with anti-calcification treatment): preferred for patients over 65, females of childbearing age, and those with anticoagulation contraindications; structural valve deterioration becomes relevant after 10–15 years • Homograft / Ross Procedure: pulmonary autograft replaces the aortic valve; excellent hemodynamics and longevity in young patients; technically demanding biventricular procedure TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR): • Indicated for intermediate-to-high surgical risk patients with severe aortic stenosis • Transfemoral access preferred (percutaneous, no sternotomy); alternative access via transapical, transaortic, or subclavian routes when iliofemoral anatomy is unfavorable • Devices available: SAPIEN 3 Ultra RESILIA (balloon-expandable), Evolut FX / PRO+ (self-expanding, supra-annular), ACURATE neo2 (self-expanding) • Intraoperative guidance: fluoroscopy + TEE; CT-derived planning with dedicated sizing software (Siemens, Materialise) • Valve-in-valve TAVR: resheathing capable devices allow repositioning; useful for degenerated surgical bioprostheses SURGICAL ACCESS APPROACHES: • Conventional median sternotomy: gold standard, full access • Minimally invasive aortic valve surgery (MIAVS) via upper mini-sternotomy (J or T incision) or right anterior mini-thoracotomy (3–6 cm incision): reduced transfusion, shorter ICU stay, faster recovery, superior cosmesis; requires dedicated perfusion strategy (femoral or axillary cannulation) • Robotic-assisted approaches: available at select advanced centers; video-endoscopic instrumentation through small port incisions ANESTHESIA & PERFUSION: • Cardiopulmonary bypass (CPB) with cold or del Nido cardioplegia for myocardial protection • TEE-guided intraoperative monitoring throughout • Cell salvage (autotransfusion) to minimize allogeneic blood use • Enhanced Recovery After Cardiac Surgery (ERACS) protocols at advanced centers reduce opioid use and hospital length of stay
Recovery
PRE-OPERATIVE PHASE (Weeks 1–2 before surgery): • Step 1 — Remote Consultation: Upload all recent echocardiography reports, cardiac CT, coronary angiography, and outpatient letters to GAF Healthcare's secure patient portal. A GAF-affiliated senior cardiac surgeon reviews the records and provides a written surgical opinion and cost estimate within 48–72 hours. • Step 2 — Visa & Travel Coordination: GAF Healthcare initiates e-Medical Visa application for India (typically approved in 3–5 business days) or UAE visit/medical visa coordination. Flight booking and airport reception are arranged. • Step 3 — Pre-Admission Workup (on arrival, Days 1–2): Full cardiac assessment including repeat TTE/TEE, ECG-gated cardiac CT if not recently performed, coronary angiography if indicated, full blood panel (CBC, CMP, coagulation, HbA1c, infectious serology), anaesthesiology review, and cardiologist case conference. Medication optimization (beta-blockade, diuretic rationalization, bridging anticoagulation if needed). • Step 4 — Surgical Planning Conference: Imaging reviewed in multidisciplinary heart team (surgeon, cardiologist, cardiac anesthesiologist, perfusionist). Repair versus replacement decision finalized. Intraoperative TEE plan confirmed. INTRAOPERATIVE PHASE (Day 3–4, Surgical Day): • Step 5 — Anesthesia induction with TEE probe placement; arterial line, central venous catheter, urinary catheter insertion. • Step 6 — Surgical access: median sternotomy or minimally invasive approach (right anterior mini-thoracotomy or upper mini-sternotomy); femoral or central cannulation for cardiopulmonary bypass. • Step 7 — Cardioplegic arrest; aortic cross-clamp applied; aortotomy performed under direct vision. • Step 8 — Intraoperative valve assessment: cusp morphology quantified with caliper; repair maneuvers executed according to pre-planned strategy (cusp resuspension, annuloplasty, VSARR, or Ozaki neocuspidization). • Step 9 — Intraoperative TEE immediately after de-airing and cross-clamp release: assessment of residual regurgitation (target: none or trivial), mean gradient, and LV function. Repair revision performed if result is suboptimal before closing. • Step 10 — CPB weaning; hemostasis; chest closure with mediastinal drains; transfer to cardiac ICU. POST-OPERATIVE PHASE — ICU (Days 1–3 post-op): • Step 11 — Extubation target: within 4–8 hours of surgery under ERACS protocols (or next morning in complex cases). • Step 12 — Hemodynamic monitoring: arterial line, central venous pressure, urine output targets >0.5 mL/kg/hr. • Step 13 — Pain management: multimodal analgesia (parasternal blocks, NSAIDs, acetaminophen, minimal opioids). • Step 14 — Anticoagulation initiation: heparin bridging (if mechanical valve or post-repair AF risk), transitioning to warfarin (mechanical) or aspirin (biological repair/replacement). • Step 15 — Physiotherapy begins Day 1 post-op: deep breathing exercises, incentive spirometry, limb exercises in bed. POST-OPERATIVE PHASE — STEP-DOWN WARD (Days 4–12): • Step 16 — Drain removal (typically Day 1–2 post-op); ambulation beginning Day 2–3; sternal precautions counseled. • Step 17 — Repeat echocardiogram (Days 5–7): confirms repair durability, LV recovery, absence of paravalvular leak or new pericardial effusion. • Step 18 — Dietary normalization; diuretic weaning; optimized discharge medications prescribed (ACE inhibitor or ARB, beta-blocker, anticoagulant/antiplatelet as indicated). • Step 19 — Discharge from hospital: typically Days 7–12 post-op. Discharge summary and imaging data provided in digital format for home cardiologist. POST-DISCHARGE RECOVERY IN COUNTRY (Weeks 2–6): • Step 20 — Outpatient review at 2 weeks post-op: wound check, suture/staple removal, ECG, blood panel (INR monitoring for anticoagulated patients), and echocardiography if any concerns. • Step 21 — Cardiac rehabilitation begins: supervised low-intensity walking program, progressive activity escalation. • Step 22 — Clearance for air travel (fit-to-fly assessment): short-haul flights permitted from approximately Week 4; long-haul flights (>6 hours) from Weeks 6–8. Clearance based on stable sternum (clinical assessment), INR within therapeutic range, no pericardial effusion on echo, and absence of arrhythmia. LONG-TERM MILESTONES: • 6 weeks: sternal precautions typically lifted; driving permitted • 6–8 weeks: return to sedentary/desk work • 3 months: return to moderate physical activity • 6 months: full echocardiographic assessment of repair durability • Annual echocardiography: lifelong surveillance for repair integrity, aortic root dimensions, and LV function
Risks to be aware of
Aortic valve repair and replacement carry well-characterized risks that patients must discuss candidly with their surgical team. In-hospital mortality for isolated aortic valve surgery in low-to-intermediate risk patients (STS-PROM <4%) at high-volume centers is below 1–2%, but rises with advancing age, reduced LV ejection fraction, concomitant procedures, and comorbidities. Specific risks include: stroke or transient ischaemic attack (1–3%), driven by air embolism, calcium debris, or atrial fibrillation in the perioperative period — mitigated by epiaortic ultrasound, carbon dioxide field flooding, and antiarrhythmic prophylaxis; new-onset atrial fibrillation (20–40%), typically transient but requiring rate control and anticoagulation; complete heart block requiring permanent pacemaker implantation (1–3%, higher with heavy annular decalcification); acute kidney injury (5–10%, usually transient; risk reduced with off-pump perfusion strategies and careful hemodynamic management); wound complications including deep sternal wound infection (0.5–1%); and bleeding requiring re-exploration (2–5%). Repair-specific risks include residual or recurrent aortic regurgitation (requiring reoperation in approximately 10–15% of patients at 10 years, depending on repair complexity and etiology) — rates are significantly lower in specialist centers performing >50 repairs per year. Patients receiving mechanical prostheses accept lifelong anticoagulation with warfarin (INR target 2.0–3.0, or 1.5–2.0 with On-X valve), which carries an annual major bleeding risk of 1–2% and thromboembolic risk of 0.5–1%. Biological valve recipients avoid anticoagulation but face structural valve deterioration (SVD) at a rate of approximately 1% per year after the first decade, with younger patients at higher risk. TAVR-specific risks include permanent pacemaker requirement (5–25% depending on device), vascular access complications (1–3%), and paravalvular leak, which — even when mild — has been associated with worse long-term outcomes. All risks must be risk-stratified individually using validated scores (STS-PROM, EuroSCORE II, and for TAVR, the PARTNER trial risk framework), and discussed in a multidisciplinary heart team meeting before any intervention is scheduled.
Why GAF Healthcare
GAF Healthcare provides a fully integrated non-medical support infrastructure to ensure that international patients can focus entirely on their clinical care. VISA ASSISTANCE — INDIA: GAF Healthcare's coordination team initiates the e-Medical Visa (eMV) application process on the patient's behalf as soon as a hospital acceptance letter is issued. The eMV allows a stay of up to 60 days (extendable) and is typically approved within 3–5 business days. Attendant visas for accompanying family members are processed simultaneously. GAF provides all required documentation templates including the hospital invitation letter, treatment cost estimates, and letter of appointment. VISA ASSISTANCE — UAE: Citizens of approximately 50 countries enjoy visa-on-arrival or visa-free access to the UAE for up to 30–90 days. For nationalities requiring a pre-arranged visa, GAF coordinates a UAE Medical Visa or tourist visa through its partner facilitation channels, typically processed in 5–7 business days. Patients from the Gulf Cooperation Council (GCC) require no visa. AIRPORT TRANSFERS & GROUND LOGISTICS: A dedicated GAF Healthcare patient liaison meets every patient at the arrival terminal with a clearly identified sign, assists with luggage, and provides a comfortable, medically appropriate vehicle transfer directly to the hospital or pre-arranged accommodation. Return transfers to the airport are coordinated around the surgeon's fit-to-fly clearance, not a fixed calendar date. DEDICATED PATIENT COORDINATOR: Each patient is assigned a personal GAF Healthcare case coordinator — available 7 days a week via WhatsApp, phone, and email — who manages appointment scheduling, inter-department communication, report collection, translation requests, and any logistical escalations during the entire in-country stay. MEDICAL TRANSLATION & INTERPRETATION: For patients who are not fluent in English, Hindi, or Arabic, GAF arranges professional medical interpreters (available in Arabic, Russian, French, Swahili, Uzbek, and other languages on request) for all surgical consent discussions, post-operative briefings, and discharge counseling sessions. ATTENDANT ACCOMMODATION: GAF Healthcare has negotiated preferred rates at partner hotels and serviced apartments within 5–15 minutes of all affiliated hospitals in India (Delhi, Mumbai, Chennai, Bangalore, Hyderabad) and the UAE (Dubai, Abu Dhabi). Options range from budget-friendly guest houses to premium hotel suites. In-hospital attendant bedding arrangements within the patient's private room are coordinated at the time of admission. POST-DISCHARGE FOLLOW-UP COORDINATION: Before the patient departs for home, GAF provides a fully compiled digital medical dossier including operative reports, histopathology results (if applicable), echocardiogram recordings, discharge medications list, and a structured letter for the patient's home cardiologist. Teleconsultation follow-ups with the operating surgeon are arranged at 4 weeks and 3 months post-operatively.
Common questions about Aortic Valve Repair
What is the cost of Aortic Valve Repair in India vs. the UAE?
How long do I need to stay in the country before I am fit to fly home after Aortic Valve Repair?
What is the success rate of Aortic Valve Repair, and how durable is the repair?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Aortic Valve Repair in Dubai, UAE
Discover the Top Hospitals for Aortic Valve Repair in Dubai, UAE
This page lists 3 accredited cardiology hospitals in Dubai, UAE, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about aortic valve repair in Dubai, UAE
How many cardiology hospitals are listed in Dubai, UAE?
How do you choose which hospitals to list?
How much does treatment cost in UAE?
Are there cardiology hospitals for this in other UAE cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for aortic valve repair in Dubai, UAE.
Contact us to report an inaccuracy on this page.